NO20031408L - Modulering av transkripsjonen av pro-inflammatoriske genprodukter - Google Patents

Modulering av transkripsjonen av pro-inflammatoriske genprodukter

Info

Publication number
NO20031408L
NO20031408L NO20031408A NO20031408A NO20031408L NO 20031408 L NO20031408 L NO 20031408L NO 20031408 A NO20031408 A NO 20031408A NO 20031408 A NO20031408 A NO 20031408A NO 20031408 L NO20031408 L NO 20031408L
Authority
NO
Norway
Prior art keywords
transcription
pro
modulation
gene products
inflammatory gene
Prior art date
Application number
NO20031408A
Other languages
English (en)
Other versions
NO20031408D0 (no
Inventor
Markus Hecker
Andreas H Wagner
Original Assignee
Avontec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avontec Gmbh filed Critical Avontec Gmbh
Publication of NO20031408L publication Critical patent/NO20031408L/no
Publication of NO20031408D0 publication Critical patent/NO20031408D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
NO20031408A 2000-10-06 2003-03-27 Modulering av transkripsjonen av pro-inflammatoriske genprodukter NO20031408D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10049549A DE10049549A1 (de) 2000-10-06 2000-10-06 Modulation der Transkription pro-inflammatorischer Genprodukte
DE10059144A DE10059144A1 (de) 2000-10-06 2000-11-29 Modulation der Transkription pro-inflammatorischer Genprodukte
PCT/DE2001/003835 WO2002029044A2 (de) 2000-10-06 2001-10-04 Modulation der transkription pro-inflammatorischer genprodukte

Publications (2)

Publication Number Publication Date
NO20031408L true NO20031408L (no) 2003-03-27
NO20031408D0 NO20031408D0 (no) 2003-03-27

Family

ID=26007280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031408A NO20031408D0 (no) 2000-10-06 2003-03-27 Modulering av transkripsjonen av pro-inflammatoriske genprodukter

Country Status (11)

Country Link
US (2) US7524949B2 (no)
EP (1) EP1325122A2 (no)
JP (1) JP2004510787A (no)
CN (1) CN100436578C (no)
AU (2) AU2002223470B2 (no)
CA (1) CA2424604A1 (no)
DE (2) DE10049549A1 (no)
NO (1) NO20031408D0 (no)
PL (1) PL362987A1 (no)
RU (1) RU2003107669A (no)
WO (1) WO2002029044A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
SG176716A1 (en) * 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
WO2015095636A2 (en) * 2013-12-19 2015-06-25 The Children's Hospital Of Philadelphia Interferon regulatory factor 1 (irf1) decoys and methods of use thereof
CN103751804B (zh) * 2014-01-23 2015-09-30 武汉大学 干扰素调节因子4(irf4)基因在冠状动脉粥样硬化性心脏病中的应用
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли
CN104258419A (zh) * 2014-09-29 2015-01-07 武汉大学 干扰素调节因子1基因在治疗动脉粥样硬化中的应用
CN107580470B (zh) * 2015-01-15 2021-06-22 皇家飞利浦有限公司 瞬时流量储备-计算机断层摄影
CN106620719A (zh) * 2016-10-20 2017-05-10 武汉大学 干扰素调节因子1及其抑制剂在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
WO2020101880A1 (en) * 2018-11-14 2020-05-22 Oklahoma Medical Research Foundation Compositions and methods of treating systemic lupus erythematosus
WO2020131717A1 (en) * 2018-12-16 2020-06-25 Figene, Llc Therapeutic uses of gene edited fibroblasts
CN114948965B (zh) * 2022-07-18 2023-11-10 四川大学华西第二医院 一种化合物在制备防治组织损伤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3847366B2 (ja) 1996-02-22 2006-11-22 アンジェスＭｇ株式会社 アンチセンスオリゴヌクレオチドを用いた固定性分裂終了細胞増殖剤
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
AU5052999A (en) * 1998-07-25 2000-02-21 Astrazeneca Limited Human ccr-2 gene polymorphisms
HK1042706A1 (zh) * 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
WO2000044407A2 (en) * 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
BR0006019A (pt) * 1999-04-06 2001-03-13 Univ East Carolina Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante
JP2002541795A (ja) * 1999-04-12 2002-12-10 リボザイム・ファーマシューティカルズ・インコーポレーテッド 核酸分子を用いるリプレッサー遺伝子の制御

Also Published As

Publication number Publication date
DE10059144A1 (de) 2002-07-04
JP2004510787A (ja) 2004-04-08
US7524949B2 (en) 2009-04-28
US20040048820A1 (en) 2004-03-11
DE10049549A1 (de) 2002-05-02
AU2347002A (en) 2002-04-15
EP1325122A2 (de) 2003-07-09
US20090221686A1 (en) 2009-09-03
CA2424604A1 (en) 2003-04-02
PL362987A1 (en) 2004-11-15
CN1468305A (zh) 2004-01-14
WO2002029044A3 (de) 2002-12-12
NO20031408D0 (no) 2003-03-27
CN100436578C (zh) 2008-11-26
WO2002029044A2 (de) 2002-04-11
AU2002223470B2 (en) 2007-01-04
RU2003107669A (ru) 2004-11-20

Similar Documents

Publication Publication Date Title
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20031408L (no) Modulering av transkripsjonen av pro-inflammatoriske genprodukter
NO20031229D0 (no) Fremgangsmåte for fremstilling av börstevarer
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
DK1341414T3 (da) Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter
FI20011622A0 (fi) Menetelmä sitalopraamin valmistamiseksi
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
NO20030163L (no) Fremgangsmate for fremstilling av olefiner
AU2002223470A1 (en) Modulation of the transcription of pro-inflammatory gene products
FI20000976L (fi) Tuotteita
NO20013818D0 (no) Mikrobiell fremgangsmåte for fremstilling av pravastatin
ITMI20001827A0 (it) Medicamento antinfiammatorio
NO20025423L (no) Fremgangsmate for fremstilling av Citalopram
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
NO20021118D0 (no) Fremgangsmåte for fremstilling av citalopram
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20023702L (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20012551D0 (no) Datamaskinbasert produktspesifikasjon
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20025765L (no) Kombinasjonssett for behandling av malaria
DE60009048D1 (de) Herstellung von norlabdanoxid
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
AU2001253431A1 (en) Haplotypes of the f9 gene
FI20010791A0 (fi) Menetelmä liimapuutuotteiden valmistamiseksi
AU2001276857A1 (en) Haplotypes of the gcnt1 gene